MAGISTRONI, VERA
 Distribuzione geografica
Continente #
NA - Nord America 5.826
EU - Europa 2.862
AS - Asia 2.340
SA - Sud America 320
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 1
Totale 11.401
Nazione #
US - Stati Uniti d'America 5.672
SG - Singapore 925
CN - Cina 661
DE - Germania 603
SE - Svezia 402
RU - Federazione Russa 391
IT - Italia 375
IE - Irlanda 356
HK - Hong Kong 317
BR - Brasile 261
UA - Ucraina 230
GB - Regno Unito 184
VN - Vietnam 171
CA - Canada 118
FI - Finlandia 79
FR - Francia 64
IN - India 63
TR - Turchia 42
BE - Belgio 34
PL - Polonia 30
DK - Danimarca 28
ID - Indonesia 28
NL - Olanda 28
ZA - Sudafrica 27
BD - Bangladesh 25
KR - Corea 25
MX - Messico 25
AR - Argentina 24
JP - Giappone 19
IQ - Iraq 13
ES - Italia 12
AT - Austria 10
EC - Ecuador 10
LT - Lituania 10
BG - Bulgaria 9
EU - Europa 9
SA - Arabia Saudita 9
VE - Venezuela 7
CZ - Repubblica Ceca 6
IR - Iran 6
CH - Svizzera 5
CO - Colombia 5
NP - Nepal 5
PE - Perù 5
PK - Pakistan 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
KE - Kenya 4
MA - Marocco 4
CL - Cile 3
IL - Israele 3
MY - Malesia 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
EG - Egitto 2
HN - Honduras 2
JM - Giamaica 2
JO - Giordania 2
KG - Kirghizistan 2
MU - Mauritius 2
NO - Norvegia 2
PY - Paraguay 2
RO - Romania 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AU - Australia 1
BN - Brunei Darussalam 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
RS - Serbia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 11.401
Città #
Ann Arbor 1.035
Ashburn 549
Singapore 549
Woodbridge 445
Chandler 354
Dublin 348
Fairfield 332
Hong Kong 315
Frankfurt am Main 269
Houston 269
Jacksonville 224
Wilmington 209
Dearborn 205
Milan 167
New York 156
Seattle 129
Beijing 116
Cambridge 107
Santa Clara 107
Los Angeles 103
Göttingen 91
Princeton 91
Dallas 81
Shanghai 79
Nanjing 61
Hefei 49
Ho Chi Minh City 49
Altamura 41
Munich 41
Lachine 38
The Dalles 37
Lawrence 35
Moscow 35
Brussels 34
São Paulo 34
Chicago 33
Fürstenwalde 32
Boardman 29
Hanoi 29
Dong Ket 27
Toronto 27
San Diego 26
Fremont 25
Warsaw 25
Buffalo 24
Shenyang 24
San Jose 23
Helsinki 21
Jakarta 21
London 20
Montreal 19
Seoul 19
Tianjin 19
Andover 18
Guangzhou 16
Ottawa 16
Tokyo 16
Johannesburg 15
Changsha 14
Council Bluffs 14
Huizen 14
Nuremberg 14
Atlanta 13
Hebei 13
Jinan 13
Nanchang 13
Boston 12
Brooklyn 12
Jiaxing 12
Orem 12
Turku 12
Denver 11
Manchester 11
Stockholm 11
Chennai 10
Kunming 10
Lissone 10
Falls Church 9
Mexico City 9
Mumbai 9
Pune 9
Romola 9
Salt Lake City 9
Ankara 8
Düsseldorf 8
Kocaeli 8
Norwalk 8
Plovdiv 8
Rome 8
San Francisco 8
Verona 8
Vienna 8
Brasília 7
Haiphong 7
Nürnberg 7
Poplar 7
Auburn Hills 6
Charlotte 6
Edmonton 6
Hangzhou 6
Totale 7.717
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 516
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 410
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 397
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 385
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 359
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 356
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 353
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 323
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 320
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 311
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 308
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 305
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 287
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 282
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 278
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 277
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 275
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 273
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 271
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 269
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 267
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 257
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 256
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 249
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 238
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 230
Epigenetic Silencing of the Pro-Apoptotic Bim Gene in Glucocorticoid Poor-Responsive Pediatric Acute Lymphoblastic Leukemia, and Its Reversal by Histone Deacetylase Inhibition 226
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 220
Whole-exome sequencing of matched chronic phase and blast crisis CML samples to reveal mechanisms of blast crisis transformation 219
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 218
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 217
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants 215
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 207
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 197
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 187
BIM promoter is epigenetically silenced in malignant lymphoid cells, leading to downregulation of BIM expression and protection from apoptosis 184
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 181
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 172
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents 170
Mechanisms of Bim epigenetic silencing in anaplastic large cell lymphoma 169
Bim promoter is highly methylated in malignant lymphoid cell lines, leading to downregulation of Bim expression and protection from apoptosis 154
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 146
Reactivation of an Epigenetic Silenced Tumor Suppressor Gene BIM in Anaplastic Large Cell Lymphoma Leads to massive Apoptosis 145
Epigenetic changes at the bim locus associated with glucocorticoid resistance in human lymphoid malignancies 138
Reversal of glucocorticoid resistance in human lymphoid malignancies with histone deacetylase inhibitors 137
Role of TMPRSS2/ERG in cellular transformation 129
Totale 11.683
Categoria #
all - tutte 36.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.897


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021552 0 0 0 0 0 0 105 82 96 115 63 91
2021/2022687 47 67 103 45 47 62 38 32 32 61 47 106
2022/20231.298 157 426 113 127 94 181 15 64 87 5 19 10
2023/2024930 23 32 33 47 126 285 205 15 59 16 4 85
2024/20251.716 112 190 108 102 156 58 102 31 124 314 156 263
2025/20262.482 503 222 359 564 568 218 48 0 0 0 0 0
Totale 11.683